ReviewPrecision radiation oncology2025
Application of high-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal cancer.
Review in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A nomogram based on body composition and the prognostic nutritional index to predict early postoperative complications of colorectal cancer.BMC medical imaging · 2026Article
- Influence of Diagnostic and Treatment Delays on Survival Outcomes in Patients With Locally Advanced Rectal Cancer: A Multi-Center Retrospective Cohort Study.Cancer medicine · 2026Article
- HALP score outperforms systemic inflammatory biomarkers for prognosis in locally advanced rectal cancer.Biomolecules & biomedicine · 2026Observational
- NovelFrontiers in medicine · 2026Article
- A novel frameshift variant inFrontiers in medicine · 2026Article
- Comparison of reduced FOV diffusion-weighted imaging of rectal cancer at 5.0T ultra-high field versus 3.0T MRI: image quality and histopathological T staging.BMC medical imaging · 2025Article
- Application of high-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal cancer.Precision radiation oncology · 2025Review
- Molecular analysis of three DNA mismatch repair protein variants in Chinese families with suspected Lynch syndrome.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study evaluates the efficacy, toxicity, and survival impact of high-dose-rate endorectal brachytherapy (HDR-EBT) as neoadjuvant therapy for locally advanced rectal cancer. Methods: A review of 16 studies from PubMed, Embase, and Web of Science (1990-2023) was conducted. Results: Patients treated with HDR-EBT alone had a pathological complete response (pCR) rate of 23.7%-35.3% (mean: 24.3%), anal preservation rate of 12.2%-74.9% (mean: 41.8%), and 5-year progression-free survival rate of 64.6%-65.4% (mean: 65.3%). When combined with concurrent long-term radiotherapy and chemotherapy, pCR rates improved from 18.1%-55.0% (mean: 31.0%), with anal preservation rates of 39.6%-51.4% (mean: 45.3%). However, overall survival did not significantly improve. Conclusion: Integrating advanced techniques such as intensity-modulated radiation therapy (IMRT) with HDR-EBT shows promise. This approach particularly benefits patients ineligible for surgery or those adopting a watch-and-wait strategy after complete clinical remission, thus highlighting the potential of HDR-EBT in this treatment landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.